MDT-AP-0417
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 54.96
- os_event
- false
- age_years
- 18
- sex
- M
- new_clusters
- S1
- umap1_2d
- -0.749993491
- umap2_2d
- -11.68264101
- umap1_3d
- -2.956822236
- umap2_3d
- 0.023670518
- umap3_3d
- 6.812836515
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.580
- MYC_TARGETS_V1+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.320
- MITOTIC_SPINDLE+0.260
- OXIDATIVE_PHOSPHORYLATION+0.260
- WNT_BETA_CATENIN_SIGNALING+0.250
- PEROXISOME+0.200
- E2F_TARGETS+0.180
- GLYCOLYSIS+0.160
- MTORC1_SIGNALING+0.120
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- INFLAMMATORY_RESPONSE-0.330
- ALLOGRAFT_REJECTION-0.310
- COMPLEMENT-0.310
- ANGIOGENESIS-0.290
- SPERMATOGENESIS-0.270
- PANCREAS_BETA_CELLS-0.260
- KRAS_SIGNALING_UP-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_53M8PP88 | Ependymoma NOS | — | 0.851 |
| 2 | TCGA-2F-A9KP-01A-11R-A38B-07 | — | — | 0.843 |
| 3 | TCGA-UF-A71A-06A-11R-A39I-07 | — | — | 0.840 |
| 4 | 268A4E05-3389-4F46-976F-3EC5E269AC2D | — | — | 0.838 |
| 5 | BS_53M8PP88 | EPN | EPN Tumor | 0.836 |
| 6 | TCGA-33-A4WN-01A-11R-A262-07 | — | cohortSQ2 | 0.835 |
| 7 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.831 |
| 8 | SAMN03290927 | — | — | 0.831 |
| 9 | BS_WVW3W6ZB | ATRT | — | 0.830 |
| 10 | EPT0810 | EPN | Posterior Fossa EPN | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |